Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)
Status:
NOT_YET_RECRUITING
Trial end date:
2031-06-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, multi-cohort clinical trial designed to evaluate the preliminary efficacy and safety of zanidatamab in combination with tislelizumab and chemotherapy/radiotherapy for patients with HER2-positive locally advanced or metastatic gastrointestinal tumors.
Phase:
PHASE2
Details
Lead Sponsor:
Tao Zhang
Treatments:
Capecitabine Oxaliplatin S 1 (combination) zanidatamab